Stephan Herbertz

1.4k total citations · 1 hit paper
10 papers, 1.1k citations indexed

About

Stephan Herbertz is a scholar working on Molecular Biology, Oncology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Stephan Herbertz has authored 10 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Molecular Biology, 7 papers in Oncology and 4 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Stephan Herbertz's work include Lung Cancer Treatments and Mutations (4 papers), Glycosylation and Glycoproteins Research (3 papers) and Peptidase Inhibition and Analysis (3 papers). Stephan Herbertz is often cited by papers focused on Lung Cancer Treatments and Mutations (4 papers), Glycosylation and Glycoproteins Research (3 papers) and Peptidase Inhibition and Analysis (3 papers). Stephan Herbertz collaborates with scholars based in Germany, Denmark and United Kingdom. Stephan Herbertz's co-authors include Shawn T. Estrem, Christopher A. Slapak, Jon Zugazagoitia, Gerald Schmid‐Bindert, Karim A. Benhadji, Irene Ferrer, Luis Paz‐Ares, Ivelina Gueorguieva, Michael Lahn and William J. John and has published in prestigious journals such as Oncogene, Annals of Oncology and Journal of Thoracic Oncology.

In The Last Decade

Stephan Herbertz

10 papers receiving 1.1k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Clinical development of galunisertib (LY2157299 monohydrate), a small molecule inhibitor of transforming growth factor-beta signaling pathway

2015 453 citations Michael Lahn, Stephan Herbertz et al. Drug Design Development and Therapy profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Stephan Herbertz Germany	7	584	426	245	205	195	10	1.1k
Laura Castellini United States	16	434 0.7×	351 0.8×	153 0.6×	278 1.4×	316 1.6×	19	1.0k
Amarsanaa Jazag Japan	20	885 1.5×	443 1.0×	141 0.6×	185 0.9×	250 1.3×	29	1.4k
Catalin Mihalcioiu Canada	14	391 0.7×	422 1.0×	156 0.6×	155 0.8×	283 1.5×	38	1000
Dominic Chih‐Cheng Voon Japan	20	856 1.5×	355 0.8×	165 0.7×	267 1.3×	260 1.3×	41	1.3k
Laith Dabbagh Canada	15	549 0.9×	546 1.3×	194 0.8×	212 1.0×	160 0.8×	23	1.3k
Brian Cao United States	17	638 1.1×	381 0.9×	230 0.9×	92 0.4×	174 0.9×	37	1.2k
Nuran Bektas Germany	13	642 1.1×	269 0.6×	103 0.4×	206 1.0×	132 0.7×	15	1.0k
Siân Rizzo United Kingdom	15	601 1.0×	301 0.7×	131 0.5×	138 0.7×	184 0.9×	25	1.1k
Kavitha Balaji United States	9	320 0.5×	381 0.9×	142 0.6×	229 1.1×	105 0.5×	15	829
Mark T. Boyd United Kingdom	21	710 1.2×	562 1.3×	162 0.7×	95 0.5×	281 1.4×	36	1.2k

Countries citing papers authored by Stephan Herbertz

Since Specialization

Citations

This map shows the geographic impact of Stephan Herbertz's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Stephan Herbertz with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Stephan Herbertz more than expected).

Fields of papers citing papers by Stephan Herbertz

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Stephan Herbertz. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Stephan Herbertz. The network helps show where Stephan Herbertz may publish in the future.

Co-authorship network of co-authors of Stephan Herbertz

This figure shows the co-authorship network connecting the top 25 collaborators of Stephan Herbertz. A scholar is included among the top collaborators of Stephan Herbertz based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Stephan Herbertz. Stephan Herbertz is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

10 of 10 papers shown

Baik, Christina S., Christine M. Lovly, Tejas Patil, et al.. (2024). PP01.115 Real-World Characteristics and Outcomes Among Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) and HER2 Mutations. Journal of Thoracic Oncology. 19(7). e49–e50. 1 indexed citations

Nagasaka, Misako, et al.. (2024). 1298P Epidemiological and genomic features of patients (pts) with advanced/metastatic (a/m) non-small cell lung cancer (NSCLC) with HER2/ERBB2 mutations within and outside the tyrosine kinase domain (TKD). Annals of Oncology. 35. S826–S826. 1 indexed citations

Ferrer, Irene, Jon Zugazagoitia, Stephan Herbertz, et al.. (2018). KRAS-Mutant non-small cell lung cancer: From biology to therapy. Lung Cancer. 124. 53–64. 229 indexed citations

Lahn, Michael, Stephan Herbertz, Anja J. Stauber, et al.. (2015). Clinical development of galunisertib (LY2157299 monohydrate), a small molecule inhibitor of transforming growth factor-beta signaling pathway. Drug Design Development and Therapy. 4479–4479. 453 indexed citations breakdown →

Markova, Boyka, Patricia S. Hähnel, Stefan Kasper, et al.. (2011). Pharmacologic inhibition of mTOR antagonizes the cytotoxic activity of pemetrexed in non-small cell lung cancer. Journal of Cancer Research and Clinical Oncology. 138(4). 545–554. 6 indexed citations

Mollenhauer, Jan, Hanna Müller, Stefan Lyer, et al.. (2002). The SRCR/SID region of DMBT1 defines a complex multi‐allele system representing the major basis for its variability in cancer. Genes Chromosomes and Cancer. 35(3). 242–255. 36 indexed citations

Mollenhauer, Jan, Burkhard Helmke, Hanna Müller, et al.. (2002). Sequential changes of the DMBT1 expression and location in normal lung tissue and lung carcinomas. Genes Chromosomes and Cancer. 35(2). 164–169. 53 indexed citations

Mollenhauer, Jan, Stephan Herbertz, Burkhard Helmke, et al.. (2001). Deleted in Malignant Brain Tumors 1 is a versatile mucin-like molecule likely to play a differential role in digestive tract cancer.. PubMed. 61(24). 8880–6. 80 indexed citations

Mollenhauer, Jan, Stephan Herbertz, Uffe Holmskov, et al.. (2000). DMBT1 encodes a protein involved in the immune defense and in epithelial differentiation and is highly unstable in cancer.. PubMed. 60(6). 1704–10. 153 indexed citations

10.

Mollenhauer, Jan, Uffe Holmskov, Stefan Wiemann, et al.. (1999). The genomic structure of the DMBT1 gene: evidence for a region with susceptibility to genomic instability. Oncogene. 18(46). 6233–6240. 72 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact